Related by context. All words. (Click for frequent words.) 72 endometrial cancer 70 invasive breast cancer 69 colorectal cancer 68 ovarian cancer 67 breast cancer 65 tamoxifen 64 breast cancers 64 tumor recurrence 63 colon cancer 63 prostate cancer 63 uterine cancers 62 endometrial cancers 62 recurrent VTE 62 metastatic prostate cancer 62 tamoxifen therapy 62 endometrial hyperplasia 62 endometrial carcinoma 62 distant metastases 61 contralateral breast cancer 61 colorectal adenomas 61 oophorectomy 61 postmenopausal breast cancer 61 breast cancer metastasis 61 breast tumors 60 cardiovascular disease 60 colorectal cancer CRC 60 lobular breast cancer 60 metastatic disease 60 colon polyps 60 CMV disease 60 epithelial ovarian cancer 59 hereditary breast cancer 59 atypia 59 anastrozole 59 disease progression 59 adenoma 59 adenoma recurrence 59 axillary lymph nodes 59 ductal cancer 59 ovarian cancers 59 pre menopausal 59 metastatic breast cancer 59 rectal cancer 59 pCR 59 vertebral fracture 59 prolongs survival 59 bone metastasis 59 estrogen receptor negative 59 atypical hyperplasia 59 gastric cancer 58 mammographic density 58 colon tumors 58 metastases 58 Tamoxifen 58 prostate cancer CaP 58 prostate cancers 58 heart disease 58 distant metastasis 58 advanced adenomas 58 advanced adenoma 58 adenomas 58 colorectal neoplasia 58 hormone therapy 58 letrozole 58 breast cancer recurrences 58 chlamydial infection 58 adjuvant chemotherapy 58 colorectal cancers 58 brain metastases 58 venous blood clots 58 PSADT 58 HER2 positive breast cancer 58 venous thromboembolism 58 premenopausal 58 antiplatelet therapy 58 colorectal tumors 58 premenopausal breast cancer 58 spontaneous preterm delivery 58 localized prostate cancer 57 cardiovascular mortality 57 breast carcinoma 57 MS relapses 57 polyp recurrence 57 neoadjuvant chemotherapy 57 exemestane 57 Recurrence Score 57 lobular cancer 57 lung cancer 57 postoperative mortality 57 PCa 57 menopausal hormone therapy 57 BRCA mutations 57 estrogen therapy 57 biochemical recurrence 57 recurrent venous thromboembolism 57 metastatic cancer 57 thromboembolic events 57 colorectal adenoma 57 adjuvant radiation 57 axillary dissection 57 abnormal mammogram 57 adjuvant therapy 57 tibolone 57 intensive statin therapy 57 abnormal mammograms 57 ischemic stroke 57 nonmelanoma skin cancers 56 CaP 56 bladder cancer 56 bladder cancers 56 subclinical atherosclerosis 56 prostate cancer PCa 56 cardiovascular disease CVD 56 trastuzumab 56 recurrent ovarian cancer 56 hormonal therapy 56 androgen deprivation 56 EUS FNA 56 bowel cancer 56 vasomotor symptoms 56 dutasteride 56 cardiotoxicity 56 estrogen progestin therapy 56 benign breast 56 rectal cancers 56 hormone therapy estrogen 56 serum PSA 56 tumors 56 nonvertebral fractures 56 chemoradiotherapy 56 ductal breast cancer 56 preoperative chemotherapy 56 hormone receptor positive 56 atherosclerotic disease 56 estrogen progestin combination 56 bowel cancers 56 recurrent miscarriage 56 GnRH agonists 56 lobular carcinoma 56 peritoneal cancer 56 HNSCC 56 atypical ductal hyperplasia 56 undergone hysterectomy 56 thrombotic events 56 spontaneous preterm birth 56 sentinel node biopsy 56 progesterone receptor negative 56 CMV infection 56 folate supplementation 55 EBRT 55 differentiated thyroid 55 chemoradiation 55 recurrent stroke 55 dietary fat 55 lung tumors 55 myocardial infarction 55 VTE 55 operable breast cancer 55 androgen deprivation therapy 55 atherothrombotic events 55 zoledronic acid 55 colon cancers 55 coronary artery disease 55 cardiovascular morbidity 55 distal colon cancer 55 statin therapy 55 postmenopausal 55 neoadjuvant therapy 55 albuminuria 55 melanoma 55 cerebral infarction 55 postmenopausal women 55 cystectomy 55 cabazitaxel 55 pertuzumab 55 biochemical relapse 55 Adjuvant chemotherapy 55 virologic failure 55 spine fractures 55 recurrent prostate cancer 55 cardiac dysfunction 55 folic acid intake 55 platelet reactivity 55 hip fracture 55 ductal carcinomas 55 cervical cancer 55 Hormone therapy 55 preeclampsia 55 Hepatocellular Carcinoma HCC 55 anovulatory infertility 55 contralateral breast 55 pre cancerous lesions 55 deCODE BreastCancer TM 55 pancreatic adenocarcinoma 55 recurrent myocardial infarction 55 BRCA mutation carriers 55 Breast Cancer Risk 55 cisplatin chemotherapy 55 preterm delivery 55 gastrointestinal cancers 55 estrogen receptor positive 55 neoadjuvant 55 postoperative AF 55 calcium supplementation 55 mammary tumors 55 lipid lowering therapy 55 colorectal cancer incidence 55 breast endometrial 55 pancreatic cancer 55 prostate cancer CRPC 55 locoregional recurrence 55 colorectal polyps 55 reinfarction 55 aromatase inhibitor 55 endocrine therapy 55 infarct size 55 BRCA mutation 55 axillary nodes 55 thromboembolic disease 55 clodronate 55 adjuvant radiotherapy 54 cilostazol 54 HER2 positive 54 microvascular complications 54 postoperative pulmonary 54 carotid IMT 54 endometrial 54 PSA velocity 54 CDI recurrence 54 A1c levels 54 annualized relapse 54 Barrett Esophagus 54 venous thromboembolism VTE 54 RBP4 levels 54 preventive mastectomy 54 osteoporotic fractures 54 micrometastases 54 cancer 54 HbA1C 54 menopausal symptoms 54 salpingo oophorectomy 54 thiazide diuretics 54 colorectal carcinoma 54 soy isoflavones 54 precancerous lesions 54 node metastases 54 lymph node metastases 54 malignancy 54 Ovary removal 54 testosterone supplementation 54 myocardial infarction MI 54 colorectal polyp 54 HER2 negative 54 metachronous 54 letrozole Femara 54 HER2 overexpression 54 mammary cancers 54 hip BMD 54 dose aspirin 54 thrombotic complications 54 esophageal cancers 54 recurrence 54 serum uric acid 54 pre cancerous polyps 54 postmenopausal hormone 54 HER2 expression 54 liver metastasis 54 BRCA2 mutations 54 ARIMIDEX 54 polyp detection 54 haemorrhagic stroke 54 clinically localized prostate 54 cervical lesions 54 endometriosis ovarian cysts 54 neoadjuvant treatment 54 prednisone prednisolone 54 urate levels 54 invasive carcinoma 54 advanced neoplasia 54 ovarian tumors 54 coronary artery calcium 54 ovulatory infertility 54 bilateral oophorectomy 54 gynecologic cancers 54 folate intake 54 prostate tumors 54 epithelial ovarian 54 nonfasting triglyceride levels 54 axillary node dissection 54 neoadjuvant radiation 54 recurrent atrial fibrillation 54 nonvertebral fracture 54 Zometa 54 ALND 54 cancers 54 polycystic ovary syndrome PCOS 54 CIN3 54 upper gastrointestinal bleeding 54 selenium supplementation 54 dysglycemia 54 subclinical hyperthyroidism 53 androgen suppression therapy 53 lymph node metastasis 53 lung metastasis 53 postmenopausal hormones 53 serum calcium levels 53 FOLFOX4 53 NATRECOR R 53 pre cancerous cells 53 intestinal polyps 53 postmenopausal hormone therapy 53 coronary heart 53 venous thromboembolic events 53 prostate adenocarcinoma 53 pelvic malignancies 53 nonfatal MI 53 Lp PLA2 53 CLA supplementation 53 renal toxicity 53 lymph node removal 53 hemorrhagic complications 53 androgen suppression 53 Femara 53 coronary blockages 53 ovarian cervical 53 Raloxifene 53 osteoporotic fracture 53 perioperative mortality 53 tHcy 53 colon rectal cancer 53 Lp PLA 2 53 nocturnal hypoglycaemia 53 endometrial kidney 53 elevated CRP 53 colon polyp 53 liver fibrosis 53 fibroadenomas 53 nonmetastatic 53 macrovascular 53 malignant growths 53 estrogen 53 elevated LDL cholesterol 53 recurrences 53 arterial calcification 53 GnRH agonist 53 neoplasia 53 BRCA1 mutations 53 flutamide 53 pegylated liposomal doxorubicin 53 sentinel lymph node biopsy 53 serous ovarian cancer 53 troponin T 53 intravenous bisphosphonates 53 knee osteoarthritis 53 ovarian carcinoma 53 thromboembolism 53 gynecological cancer 53 serum cholesterol 53 alteplase 53 sentinel nodes 53 curative resection 53 de ath 53 axillary lymph node dissection 53 postoperative atrial fibrillation 53 5-FU/LV 53 hormone deprivation 53 Celecoxib APC trial 53 rosuvastatin #mg 53 antigen PSA 53 carotid stenosis 53 cetuximab Erbitux 53 decitabine 53 gout flares 53 acute myelogenous leukemia AML 53 nocturnal hypoglycemia 53 pelvic lymphadenectomy 53 atypical fractures 53 carotid atherosclerosis 53 tumor progression 53 gynecologic cancer 53 ticlopidine 53 locoregional 53 Rectal cancer 53 precancerous polyp 53 LDL oxidation 53 raloxifene Evista 53 Cristofanilli 53 hormone therapy HT 52 post menopausal 52 hepatocellular carcinoma 52 bone resorption 52 LV dysfunction 52 cytoreductive surgery 52 gynecological cancers 52 thromboembolic 52 prophylactic mastectomy 52 malignancies 52 metastatic tumors 52 intima media thickness 52 statins 52 Invasive Breast Cancer 52 celecoxib 52 liver metastases 52 bowel polyps 52 Tavocept 52 Subgroup analysis 52 exemestane Aromasin 52 urothelial carcinoma 52 coronary calcification 52 androgen ablation 52 ABCB1 52 ASCUS 52 breast conserving 52 premature menopause 52 metastasis 52 lymphadenectomy 52 situ LCIS 52 renal cell carcinomas 52 undergoing radical prostatectomy 52 SLNB 52 pelvic lymph nodes 52 esophageal squamous cell carcinoma 52 invasive ductal 52 antigen PSA levels 52 subclinical hypothyroidism 52 urothelial cancer 52 SHBG 52 coronary disease 52 alpha carotene 52 glomerular filtration 52 vertebral fractures 52 uveal melanoma 52 malignant lesions 52 thyrotropin 52 serum phosphate 52 chemopreventive agent 52 KIF6 carriers 52 invasive cervical cancer 52 alcoholic cirrhosis 52 baseline HbA1c 52 relapsed ovarian cancer 52 variceal bleeding 52 liver cancer 52 BRCA carriers 52 treat menopausal symptoms 52 Kaplan Meier analysis 52 glycosylated hemoglobin HbA1c 52 recurrent preterm birth 52 anti androgen 52 postmenopausal hormone replacement 52 myocardial ischemia 52 bone metastases 52 hormone receptor negative 52 aneurysmal subarachnoid hemorrhage 52 lung cancers 52 lymph node dissection 52 Premenopausal women 52 thromboembolisms 52 reblockage 52 tumor shrinkage 52 antihypertensive therapy 52 lymph node involvement 52 catheter angiography 52 acute coronary 52 gallstone disease 52 urinary bladder cancer 52 abnormal Pap test 52 osteoporosis 52 adenomatous polyps 52 TACE 52 eplerenone 52 hepatocellular carcinoma HCC 52 undergo prostate biopsy 52 precursor lesions 52 neural tube birth defects 52 metastatic colon cancer 52 HbA1c levels 52 Neoadjuvant 52 PROCHIEVE ® 8 52 cardiovascular hospitalization 52 BRCA2 mutation carriers 52 aromatase inhibitor therapy 52 clinically detectable 52 perioperative morbidity 52 mammographic breast density 52 screening mammography 52 magnesium intake 52 infusional 5-FU/LV 52 vitamin D supplementation 52 Cardiovascular Events 52 prostate pancreatic 52 prostate tumor 52 uterine tumors 52 Breast Cancer Recurrence 52 hormonal therapies 52 sudden cardiac death 52 homocysteine levels 52 carotid endarterectomy 52 preterm birth 52 bladder tumors 52 HPV infection 52 recurrent metastatic 52 SUVmax 52 ALCL 52 PASI scores 52 estrogen receptor ER 52 medullary thyroid cancer 52 risedronate 52 low expressors 52 cervical carcinoma 52 overt hepatic encephalopathy HE 52 BRCA gene mutations 52 nonmelanoma skin cancer 52 mycophenolate mofetil 52 HER2 gene 52 prostate specific antigen 52 FDG PET 52 cardiac toxicity 52 DVT PE 52 postoperative delirium 52 genital herpes infections 52 frequently benign tumor 52 screening colonoscopy 52 ischemic complications 52 MetS 52 R0 resection 52 sentinel node 52 leukemia ALL 52 chromium supplementation 52 serum urate 52 SHBG levels 51 prostate specific 51 esophageal adenocarcinoma 51 plus dexamethasone 51 SERMs 51 nonsmall cell lung cancer 51 BRCA1 mutation carriers 51 CHD mortality 51 abnormal glucose tolerance 51 preoperative radiotherapy 51 Malignant Melanoma 51 atherosclerosis 51 precancerous polyps 51 KRAS mutations 51 microalbuminuria 51 uterine ovarian 51 postoperative chemotherapy 51 cardiotoxic effects 51 BRCA2 mutation 51 PSA screening 51 Radical prostatectomy 51 venous thrombosis 51 HER2 positive tumors 51 serum urate levels 51 pre cancerous growths 51 Hydroxyurea 51 severe hypoglycemia 51 adenocarcinomas 51 cystatin C 51 oropharyngeal cancer 51 prostate cancer AIPC 51 B7 H3 51 thrombolytic therapy 51 CYP#C# [001] 51 symptomatic VTE 51 endometriosis 51 asymptomatic carotid stenosis 51 colorectal liver metastases 51 glycated hemoglobin levels 51 tamsulosin 51 severe exacerbations 51 Combination therapy 51 radical prostatectomy 51 Darapladib 51 insulin glargine 51 cerebral vasospasm 51 fluvastatin 51 gynecologic malignancy 51 clopidogrel Plavix 51 ovaries removed 51 systemic embolism 51 estrogen deficiency 51 selenium supplements 51 lipid lowering drugs 51 colorectal neoplasms 51 radiation therapy 51 cancerdefine 51 colon adenomas 51 Recurrence 51 potentially cancerous polyps 51 CYP#D# genotype 51 zoledronic acid Zometa 51 taxane therapy 51 cardiovascular hospitalizations 51 nodal metastases 51 hot flashes 51 gestational hypertension 51 bisphosphonates 51 Trastuzumab 51 VTEs 51 dexrazoxane 51 octreotide LAR 51 Estrogens 51 bicalutamide 51 temsirolimus 51 prostate cancer mCRPC 51 hip fractures 51 virologic response 51 ovarian function 51 artery blockages 51 Sentinel node biopsy 51 testicular cancers 51 N telopeptide 51 leiomyomas 51 fondaparinux 51 carotid plaques 51 tumor regrowth 51 hydroxyvitamin D levels 51 phytoestrogen intake 51 BRCA gene mutation 51 paclitaxel eluting stents 51 adjuvant endocrine therapy 51 chronic prostatitis 51 premenopausal women 51 eptifibatide 51 left ventricular ejection 51 colorectal tumor 51 binary restenosis 51 Metastatic Prostate Cancer 51 KRAS mutation 51 beta carotene supplementation 51 orchiectomy 51 statin medications 51 Androgen deprivation therapy 51 ventricular tachyarrhythmia 51 Femara letrozole 51 antiplatelet drugs 51 folate deficiency 51 telomere lengths 51 precancerous cells 51 plasma glucose levels 51 Menopausal hormone therapy 51 pancreatic lung 51 preterm deliveries 51 liver resection 51 serum clusterin levels 51 ErbB2 positive 51 Prostate Cancer Prevention 51 histological subtype 51 antitumor effect 51 urine NGAL 51 Procoralan 51 repeat revascularization 51 ovarian hormones 51 colorectal 51 non squamous NSCLC 51 platelet activation 51 cTnT levels 51 Zoledronic acid 51 specific antigen PSA 51 atheroma volume 51 STRIDE PD 51 conjugated equine estrogens 51 squamous cell lung cancer 51 surgical biopsies 51 brain shrinkage 51 grade cervical intraepithelial 51 fallopian tube carcinoma 51 Abbott Trilipix 51 dose ionizing radiation 51 radioiodine therapy 51 gastric cancers 51 Rasilez Tekturna 51 complete cytogenetic response 51 malignant melanoma 51 seminoma 51 myocardial infarctions MIs 51 bisphosphonate therapy 51 hsCRP 51 atherosclerotic lesions 51 carotid plaque 51 repigmentation 51 serum concentrations 51 invasive ductal breast cancer 51 NAFLD 51 aromatase inhibitors AIs 51 breast asymmetry 51 ximelagatran 51 glycated hemoglobin HbA1c 51 metastatic prostate 51 antiplatelet agent 51 progestin therapy 51 malignant pleural mesothelioma 51 thyroglobulin 51 cerebral microbleeds 51 neoplasia PIN 51 CYPHER Stent 51 Prostate Specific Antigen PSA 51 LQTS 51 metastatic lesions 51 radiation therapy SBRT 51 faulty BRCA genes 51 preventive mastectomies 51 obese postmenopausal 51 cardioembolic stroke 51 IV bisphosphonates 51 triglyceride concentrations 51 gefitinib 51 ToGA 51 renal flares 51 dalteparin 51 Herceptin trastuzumab 51 pancreatic cancers 51 cardiovascular disease hypertension 51 perimenopausal women 51 definite stent thrombosis 51 tumor histology 51 glycosylated hemoglobin levels 51 CHD CVD 51 cranial radiation 51 serum IGF 51 AVODART 51 gallstone formation 51 HGPIN 51 LDL cholesterol concentrations 51 nonhormonal 51 FIRMAGON 51 revascularization procedures 51 elevated triglyceride levels 51 metastatic malignant 51 CHD 51 KRAS mutations occur 51 fragility fractures 50 thrombosis 50 rebleeding 50 uterine fibroids 50 Erlotinib 50 sustained virologic response 50 postmenopause 50 dietary calcium intake 50 poorer prognosis 50 QTc interval 50 breast biopsies 50 Celecoxib 50 cranial irradiation 50 mineral density BMD 50 VT VF 50 adjuvant therapies 50 micrometastasis 50 premenstrual syndrome PMS 50 neurodevelopmental outcome 50 hemoglobin A1c HbA1c 50 basal cell carcinomas 50 Xelox 50 Aromasin 50 HER2 positive cancers 50 HIV HCV coinfected 50 polycystic ovarian syndrome PCOS 50 epithelial tumors 50 Breast cancer 50 oral FTY# 50 XELOX 50 Uterine cancer 50 cervical intraepithelial neoplasia 50 rectal carcinoma 50 relapse 50 lipid abnormalities 50 #.#ng/ml 50 prophylactic oophorectomy 50 cetuximab 50 vandetanib 50 Doxil ® 50 prostatectomy 50 teriflunomide 50 prophylactic mastectomies 50 postmenopausal estrogen 50 Velcade bortezomib 50 trans palmitoleic acid 50 Thal Dex 50 endometrial thickness 50 hemoglobin A1c levels 50 PROCHIEVE 8 50 Metastatic Breast Cancer 50 rehospitalization 50 ezetimibe simvastatin 50 testicular germ cell 50 undergo radical prostatectomy 50 nodal metastasis 50 BRAF mutation 50 renal tumors 50 TRUS biopsy 50 undergone radical prostatectomy 50 angiotensin receptor blockers 50 cosmetic breast implants 50 breast cancer Narod 50 HER2 receptor 50 GISTs 50 proliferative diabetic retinopathy 50 HER2 amplification 50 cognitive decline 50 Postmenopausal 50 perioperatively 50 5-fluorouracil/leucovorin 50 estrogen metabolites 50 abdominal adiposity 50 precancerous colon polyps 50 uncontrolled asthma 50 bezafibrate 50 endometrial tumors 50 mucosal healing 50 Colon Cancer 50 abnormal Pap 50 DFMO 50 Heavy menstrual bleeding 50 lung metastases 50 basal cell nevus syndrome 50 adiponectin levels 50 beta blocker therapy 50 autoantibodies 50 menstrual migraine 50 restenosis 50 candesartan 50 CT Colonography 50 Barrett esophagus 50 ipsilateral stroke 50 APTIVUS r 50 SRBD 50 urinary symptoms 50 male hormones androgens 50 antiestrogen 50 breast lesions 50 ovarian lung 50 homocysteine concentrations 50 thyrotropin levels 50 severe asthma exacerbations 50 RBP4 50 squamous cell cancers 50 Halaven 50 lobular involution 50 thyroid hormone levels 50 pravastatin Pravachol 50 cisplatin 50 Natalizumab 50 liver transplant recipients 50 Folfox 50 osteosarcomas 50 poor metabolizers 50 prostate carcinoma 50 oral bisphosphonate 50 systolic hypertension 50 fetal malformations 50 abnormal Pap smears 50 Cardiovascular Risk 50 acute GVHD 50 Vitamin D supplements 50 systemic lupus erythematosus SLE 50 plasma homocysteine levels 50 hyperphenylalaninemia HPA due 50 coronary artery calcification 50 Thromboembolism 50 dietary sodium 50 Adjuvant therapy 50 nonischemic 50 serum testosterone 50 β blockers 50 contrast induced nephropathy 50 Faslodex 50 ADPKD 50 antioxidant vitamin supplements 50 goserelin 50 breast carcinomas 50 melanoma tumors 50 Telintra 50 pre eclampsia 50 undergo mastectomy 50 renal cell carcinoma 50 lipoprotein 50 DCIS 50 urinary tract symptoms LUTS 50 periprocedural 50 GSTT1 50 tumor 50 D dimer 50 precancerous growths 50 gemcitabine Gemzar 50 postoperative complications 50 autoantibody levels 50 neointimal hyperplasia 50 blood Phe levels 50 Framingham Risk Score 50 osteoporotic 50 myocardial reperfusion 50 HER2 positive metastatic breast 50 chronic periodontitis 50 XIENCE V PROMUS Stent 50 PGDH 50 postoperative morbidity 50 Hodgkin lymphoma HL 50 nonfasting triglycerides 50 cutaneous melanoma 50 EDARBI 50 atopic disease 50 pleural mesothelioma 50 isoflavones 50 adiponectin 50 artherosclerosis 50 Prostate specific antigen 50 recurrent ovarian 50 Exemestane 50 antiangiogenic therapy 50 dietary folate intake 50 SLN biopsy 50 olaparib 50 antidiabetic medication 50 H. pylori eradication 50 endogenous estrogen 50 left ventricular dysfunction 50 adjuvant hormonal therapy 50 prostate carcinogenesis 50 external beam radiotherapy 50 irinotecan chemotherapy 50 bevacizumab Avastin 50 hs CRP 50 ruptured aneurysms 50 inflammatory biomarkers 50 malignant lymphoma 50 Mitomycin C 50 CALGB # [001] 50 BRCA2 gene mutation 50 diabetes mellitus DM 50 relapses 50 serum prostate 50 plaque buildup 50 relapsed MM 50 postoperative radiotherapy 50 HIV infection 50 medically inoperable 50 CVD mortality 50 androgen therapy 50 conjugated estrogens 50 thiazide diuretic 50 perioperative complications 50 placebo dexamethasone 50 colon rectal 50 paroxetine Paxil 50 confidence interval #.#-#.# 50 mammographic screening 50 MGd 50 thigh circumference 50 aromatase inhibitors 50 BRCA1 50 warfarin therapy 50 mutated BRCA1 50 ZOLINZA 50 hypertensives 50 arterial stiffening 50 KRAS status 50 dasatinib 50 colo rectal cancer 50 vaginal hysterectomy 50 gastrointestinal GI cancers 50 noncancer 50 saturated fat intake 50 mammary cancer 50 thyroid stimulating hormone 50 carcinoma 50 Tumor shrinkage 50 ICD implantation 50 Renal Cell Carcinoma 50 pneumonectomy 50 PAOD 50 severe neutropenia 49 extrapyramidal symptoms 49 metastatic colorectal 49 angiogenesis inhibitor 49 mediastinoscopy 49 Telmisartan 49 artery calcification 49 Recurrences 49 tissue plasminogen activator tPA 49 platelet function 49 platelet inhibition 49 invasive coronary angiography 49 underwent prostatectomy 49 abiraterone 49 proteinuria 49 ovulatory cycles 49 pancreatic neuroendocrine tumors 49 recurrent ischemia 49 knee OA 49 grade glioma 49 ivabradine 49 interferon beta therapy 49 occult metastases 49 prognostic variables 49 endometrial lining 49 plus progestin 49 eribulin 49 aneurysm rupture